(NEU) Neuca S.A. - Ratings and Ratios

NEUCA S.A. is a Polish company that operates in the pharmaceutical industry, engaging in wholesale distribution, manufacturing, and provision of medical services. The companys diverse business segments include wholesale distribution of medicines, manufacture of pharmaceuticals, medical operator services, clinical trials, and insurance activities.

The companys product portfolio includes a range of Rx and OTC medicines, dietary supplements, medical devices, and hygiene products under various brand names. NEUCA S.A. also provides medical care services, including prevention, diagnostics, treatment, and complementary services, as well as financing services such as insurance and occupational medicine programs.

From a business perspective, NEUCA S.A.s revenue streams can be broken down into several key areas, including wholesale distribution, manufacturing, medical services, and insurance activities. To evaluate the companys performance, key performance indicators (KPIs) such as revenue growth, gross margin, operating margin, and return on equity (ROE) can be analyzed. Given the companys ROE of 13.18%, it appears to be generating a relatively stable return on shareholder equity.

To further assess NEUCA S.A.s financial health, additional KPIs such as debt-to-equity ratio, interest coverage ratio, and dividend yield can be examined. The companys market capitalization of 3127.73M PLN and P/E ratio of 21.60 suggest that it is a relatively large-cap stock with a moderate valuation multiple. Further analysis of the companys financial statements and industry trends would be necessary to determine its investment potential.

From a growth perspective, NEUCA S.A.s expansion into new business segments, such as clinical trials and insurance activities, may provide opportunities for future growth. The companys e-commerce platform, apteline.pl, is also a potential driver of growth, given the increasing trend towards online shopping in the pharmaceutical industry.